Biobetters and the Future Biologics Market - Despite their difficult approval pathway, biobetters offer the potential for innovation and decreased healthcare costs. - BioPharm International

ADVERTISEMENT

Biobetters and the Future Biologics Market
Despite their difficult approval pathway, biobetters offer the potential for innovation and decreased healthcare costs.


BioPharm International
Volume 24, Issue 11, pp. 31-35

REFERENCES

1. EC Directive 2004/27/EC, amending Directive 2001/83/EC The Community Code Relating to Medicinal Products for Human Use (Brussels, March 2004).

2. TGA News, 57, November 2009.

3. Health Canada, Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (Ottowa, March 2010).

4. MHLW, Guideline for the Quality, Safety and Effectiveness of Biosimilar Products (in Japanese) http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/2005I210304007.pdf.

5. H. Schelleckens, Eur. J. Hosp. Pharm. 10, 243–247 (2004).

6. EMA, "Questions and Answers on the Withdrawl of the Marketing Authorization for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel" (London, 2008).

7. M. McCamish and G. Woollett, mAbs 3 (2), 212–220 (2011).

8. Federal Trade Commission, "Emerging Health Care Issues: Follow-on Biologic Drug Competition" (Washington, DC, June 2009).

9. J. Woodcock et al., Nat. Rev. Drug Disc. 6, 437–442 (2007).

10. A. Sheppard, Pharm. Tech. 22 (9), 72–74 (2010).

11. H Teissel, presentation at Sandoz Day Investors Event (September, 2008).

12. Novartis Q4/full year 2010 results, January 2011.

13. H. Grabowski, Nat. Rev. Drug Disc. 7, 479 (2008).

14. M.D. Green et al., Ann. Oncol. 14, 29–35 (2003).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here